Beyond FSH and Estradiol: A Complete Hormonal Aging Test Panel for Menopause Management

Standard hormone panels, such as FSH, estradiol, and sometimes progesterone, are the default starting point for menopause assessment. They are useful, but they are incomplete. FSH levels can fluctuate dramatically during perimenopause, rising to postmenopausal ranges in some cycles and returning to premenopausal levels in subsequent ones, making a single measurement unreliable as a diagnostic anchor. Estradiol, meanwhile, captures a snapshot of one hormone on one day, and not the cumulative biological effect of hormonal change on the immune system over months and years.

What these panels miss is the downstream biology: how shifting hormone levels are reshaping inflammation, immune function, and the pace of biological aging. That is where glycan biomarkers, and GlycanAge specifically, can fill a gap that conventional bloodwork misses regarding chronic inflammation and the underlying drivers of age-related decline.

To understand how glycan biomarkers measure the biological cost of menopause, and what that means for tracking the real-world impact of HRT and lifestyle change, read the full guide: Menopause, HRT & Biological Age: The Definitive Guide to Tracking Hormonal Aging.

What are glycans, and why do they matter for menopause?

Glycans are complex sugar molecules attached to IgG antibodies (the immune system's primary defense proteins). They act as molecular switches that regulate whether the immune system behaves in a pro-inflammatory or anti-inflammatory state. During menopause, as estradiol drops by up to 90%, IgG glycosylation shifts toward a pro-inflammatory profile, which leads to a decrease in the anti-inflammatory glycan structures associated with a youthful immune system and an increase in the pro-inflammatory ones associated with accelerated aging. This shift is measurable, stable enough to track over time, and directly tied to the hormonal changes driving menopause biology.

"Glycans attach to antibodies and regulate inflammation. They are not only biomarkers — they are functional effectors that decide whether a specific antibody will promote inflammation or suppress it."

— Prof. Gordan Lauc, Chief Scientific Officer, GlycanAge; Professor of Biochemistry and Molecular Biology, University of Zagreb

Why is FSH an unreliable marker for perimenopause?

Relying on a single FSH measurement to confirm perimenopause or menopause is clinically misleading. FSH levels fluctuate widely during the perimenopausal transition, rising to postmenopausal ranges in some cycles, then returning to premenopausal levels in others. Joint guidance from the British Menopause Society and the Royal College of Obstetricians and Gynaecologists does not recommend FSH as a standalone test for detecting menopause or perimenopause for precisely this reason. FSH results are also invalidated in women using hormonal contraception, since synthetic estrogen and progesterone suppress FSH levels independently. A precise assessment requires a clinician to review a woman's full medical history, menopausal history, and current symptoms, not a single hormone value in isolation.

"During perimenopause, hormone levels don't just gradually decline — they are very haphazard. The blood test can be quite falsely misleading. If I did a blood test on someone who is perimenopausal, I might find that their FSH is normal or even suppressed, but that's only a snapshot."

— Dr. Louise Newson, GP and Menopause Specialist, Founder of Newson Health

Can cytokines measure menopause-related inflammation?

Cytokines (chemical messengers released by the immune system to coordinate inflammatory responses) do rise in postmenopausal women, with pro-inflammatory markers including IL-6, IL-1, and TNF-alpha all elevated following estrogen deprivation. In principle, this makes them candidates for tracking menopause-related inflammation. In practice, cytokines are poor tools for this purpose: they overlap substantially with acute inflammation triggered by recent illness or injury, making it impossible to distinguish chronic hormonal-driven inflammation from a temporary immune response. Cytokine testing is also expensive and unstandardized, producing results that are difficult to compare across time points or between laboratories. Glycans, by contrast, reflect chronic, systemic inflammation rather than acute immune events, providing the stable, integrated signal that cytokines cannot.

What does a complete hormonal aging panel look like in practice?

A complete panel for menopause management combines conventional hormone markers with a biological age biomarker that captures the immune and inflammatory consequences of hormonal change. Standard markers, such as estradiol, FSH, progesterone, testosterone, DHEA-S, and thyroid function, establish the hormonal landscape. GlycanAge adds the missing layer: an objective measure of how that hormonal landscape is affecting biological aging at the immune level. Because hormone levels fluctuate daily while glycan profiles reflect cumulative biological state, the two types of data answer different questions. Hormone panels tell you what the hormonal environment looks like today; GlycanAge tells you what that environment has been doing to your biology over time.

Why does progesterone matter as much as estrogen for glycan health?

Menopause-related immune aging is driven by shifts in sex hormone balance, not estrogen decline alone. Progesterone often declines earlier than estradiol due to irregular ovulation during perimenopause, and its absence promotes glycan shifts toward a pro-inflammatory profile even when estradiol remains intermittently elevated. Progesterone exerts distinct anti-inflammatory and neuroprotective effects that are independent of estrogen's actions, meaning an HRT regimen that replaces estrogen without addressing progesterone may leave significant inflammatory biology unmanaged. For some patients, optimizing progesterone balance is as important as estrogen replacement for restoring a youthful glycan profile.

How does HRT affect biological age as measured by GlycanAge?

HRT stabilizes IgG glycosylation by counteracting the rise in pro-inflammatory agalactosylated glycans and supporting the maintenance of galactosylated and sialylated structures associated with a youthful immune profile. In clinical practice, this translates into a measurable slowing of biological aging captured by GlycanAge, with clinical testing showing biological age reductions of 5 to 25 years, depending on formulation, dosage, and individual response. Critically, not all HRT regimens produce the same glycan response. Formulation, route of administration, and dosage each influence hormonal balance and downstream glycan biology, meaning the same nominal prescription can produce very different biological outcomes in different patients. GlycanAge provides the integrated measure that tells a clinician whether a given regimen is actually working at the molecular level, or whether dose adjustment, formulation change, or broader metabolic support is needed.

How should clinicians use GlycanAge alongside hormone panels in HRT management?

GlycanAge is most valuable when used as a baseline before initiating HRT, then repeated at 3–4 months to assess biological response. At Raffaele Medical, a longevity clinic in New York City, GlycanAge testing has been incorporated into HRT management for hundreds of patients, bridging the gap between symptom assessment and molecular outcomes.

"For the first time, we can prove the systemic benefits of HRT with objective data, and that changes the conversation from short-term relief to long-term health and longevity."

— Dr. Joseph Raffaele, MD, Founder, Raffaele Medical

A lack of improvement or unexpected deterioration in GlycanAge results signals the need for clinical review, not as a diagnosis, but as an objective prompt to reassess the regimen. Unfavorable glycan profiles should be interpreted as markers of broader endocrine and immune imbalance, not simply estrogen deficiency, and may indicate the need to address progesterone balance, androgen support, stress regulation, or metabolic health alongside hormone replacement.

When should a woman retest her GlycanAge during menopause management?

The optimal retest window is 3–4 months after initiating or adjusting an HRT regimen. It is long enough for glycan biology to reflect a genuine biological shift, and short enough to be clinically actionable. Because glycan profiles change in response to sustained hormonal and lifestyle conditions rather than daily fluctuations, a result taken too soon after a change will not yet reflect the full biological response. Retesting at the right interval allows both the clinician and the patient to see whether the intervention is working at the immune level, and to make evidence-based adjustments before symptoms or risk markers escalate.

Menopause management built on FSH and estradiol alone leaves the most important biology unmeasured. GlycanAge gives clinicians and patients an objective, validated measure of how hormonal change is reshaping inflammaging in midlife and beyond, and whether HRT is actually reversing it.

If you are a menopause specialist, HRT practitioner, or longevity clinician looking to integrate glycan biomarker testing into your patient pathway, the GlycanAge Healthcare Providers page sets out how to baseline, monitor, and interpret results within a clinical workflow.

Integrate GlycanAge into your menopause care pathway → Explore GlycanAge for Healthcare Providers

External sources

• https://www.nice.org.uk/guidance/ng23/chapter/Recommendations#diagnosis-of-perimenopause-and-menopause — NICE Guideline NG23 — Menopause: Diagnosis and Management

• https://pubmed.ncbi.nlm.nih.gov/33049709/ — Jurić J, Kohrt WM, Kifer D, et al. Effects of estradiol on biological age measured using the glycan age index. Aging (Albany NY). 2020.

• https://pubmed.ncbi.nlm.nih.gov/35243255/ — Deriš H, Kifer D, Cindrić A, et al. Immunoglobulin G glycome composition in transition from premenopause to postmenopause. iScience. 2022.